{"id":62031,"date":"2026-03-31T20:43:22","date_gmt":"2026-03-31T12:43:22","guid":{"rendered":"https:\/\/flcube.com\/?p=62031"},"modified":"2026-03-31T20:43:23","modified_gmt":"2026-03-31T12:43:23","slug":"fosun-pharma-secures-nmpa-approval-for-phase-i-trial-of-attenukine-therapy-fxb0871-in-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62031","title":{"rendered":"Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE\u2122 Therapy FXB0871 in Solid Tumors"},"content":{"rendered":"\n<p><strong>Fosun Pharma<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600196:SHA\">SHA: 600196<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/2196:HKG\">HKG: 2196<\/a>) has announced <strong>NMPA approval<\/strong> to initiate a <strong>Phase I clinical trial<\/strong> of <strong>FXB0871<\/strong>, an <strong>anti-PD1-IL2 ATTENUKINE\u2122 therapy<\/strong> co-developed with <strong>Teva Pharmaceutical Industries Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/TEVA:NYSE\">NYSE: TEVA<\/a>), for the treatment of <strong>locally advanced or metastatic solid tumors<\/strong>. The approval expands the global clinical development of this innovative compound into China, complementing ongoing trials in the United States and Canada.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-summary\">Clinical Development Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Fosun Pharma (SHA: 600196, HKG: 2196)<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>FXB0871 (TEV-56278 outside Fosun territory)<\/td><\/tr><tr><td><strong>Therapeutic Class<\/strong><\/td><td>Anti-PD1-IL2 ATTENUKINE\u2122 therapy<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Locally advanced or metastatic solid tumors<\/td><\/tr><tr><td><strong>Study Phase<\/strong><\/td><td>Phase I<\/td><\/tr><tr><td><strong>Regulatory Milestone<\/strong><\/td><td>NMPA clinical trial approval<\/td><\/tr><tr><td><strong>Global Status<\/strong><\/td><td>Multi-center Phase I ongoing in US and Canada<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-structure-amp-rights-allocation\">Partnership Structure &amp; Rights Allocation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Party<\/th><th>Rights &amp; Responsibilities<\/th><\/tr><\/thead><tbody><tr><td><strong>Fosun Pharma<\/strong><\/td><td>Exclusive development, manufacturing, and commercialization rights in China (including Hong Kong SAR, Macau SAR, Taiwan) and agreed Southeast Asian countries<\/td><\/tr><tr><td><strong>Teva Pharmaceutical<\/strong><\/td><td>All development, manufacturing, and commercialization rights in rest of world<\/td><\/tr><tr><td><strong>Joint Activities<\/strong><\/td><td>Shared clinical data to accelerate global R&amp;D progress<\/td><\/tr><tr><td><strong>Technology Origin<\/strong><\/td><td>ATTENUKINE\u2122 technology developed by Teva Pharmaceutical Industries Ltd.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action-amp-preclinical-profile\">Mechanism of Action &amp; Preclinical Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Novel Platform:<\/strong> ATTENUKINE\u2122 technology provides new mechanism of action combining PD-1 blockade with IL-2 signaling<\/li>\n\n\n\n<li><strong>Therapeutic Rationale:<\/strong> Potentially offers <strong>high efficacy and low toxicity<\/strong> across broad oncology indications<\/li>\n\n\n\n<li><strong>Preclinical Results:<\/strong><\/li>\n\n\n\n<li>Demonstrated tumor regression<\/li>\n\n\n\n<li>Enhanced T-cell infiltration into tumor microenvironment<\/li>\n\n\n\n<li>Durable immune memory formation<\/li>\n\n\n\n<li><strong>Development Strategy:<\/strong> Being evaluated as monotherapy across multiple tumor types<\/li>\n\n\n\n<li><strong>Innovation Status:<\/strong> Represents cutting-edge approach to immuno-oncology combination therapy<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-business-implications\">Strategic Business Implications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Strategic Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>China Market Access<\/strong><\/td><td>NMPA approval enables rapid clinical development in world&#8217;s second-largest pharmaceutical market<\/td><\/tr><tr><td><strong>R&amp;D Localization<\/strong><\/td><td>Leverages Fosun&#8217;s advantages in localized R&amp;D and clinical practice to accelerate development timeline<\/td><\/tr><tr><td><strong>Global Coordination<\/strong><\/td><td>Complements ongoing US\/Canada trials, creating comprehensive global development program<\/td><\/tr><tr><td><strong>Pipeline Enhancement<\/strong><\/td><td>Strengthens Fosun&#8217;s oncology pipeline with innovative immuno-oncology asset<\/td><\/tr><tr><td><strong>Partnership Validation<\/strong><\/td><td>Demonstrates successful execution of Fosun&#8217;s open, global R&amp;D collaboration model<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fosun-pharma-s-innovation-strategy-context\">Fosun Pharma&#8217;s Innovation Strategy Context<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-therapeutic-focus-areas\">Therapeutic Focus Areas<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Core Indications:<\/strong> Oncology, immunology, inflammation, neurodegenerative diseases<\/li>\n\n\n\n<li><strong>Expansion Areas:<\/strong> Chronic and rare diseases<\/li>\n\n\n\n<li><strong>Goal:<\/strong> Address unmet clinical needs with sustainable, competitive pipeline<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-technology-platform-investments\">Technology Platform Investments<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Established Platforms:<\/strong> Antibodies and ADCs, small molecules, cell therapy<\/li>\n\n\n\n<li><strong>Frontier Exploration:<\/strong> Radiopharmaceuticals, small nucleic acids<\/li>\n\n\n\n<li><strong>Strategic Objective:<\/strong> Accelerate clinical translation of scientific research through enhanced early-stage innovation capabilities<\/li>\n<\/ul>\n\n\n\n<p>The FXB0871 development exemplifies Fosun&#8217;s strategy of combining global innovation partnerships with local development expertise to deliver integrated therapeutic solutions.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-outlook-amp-competitive-positioning\">Market Outlook &amp; Competitive Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Immuno-Oncology Landscape:<\/strong> Highly competitive but large market opportunity for differentiated mechanisms<\/li>\n\n\n\n<li><strong>ATTENUKINE\u2122 Differentiation:<\/strong> Novel approach may overcome limitations of current PD-1\/IL-2 combination strategies<\/li>\n\n\n\n<li><strong>China Development Advantage:<\/strong> Faster patient recruitment and lower clinical trial costs compared to Western markets<\/li>\n\n\n\n<li><strong>Commercial Potential:<\/strong> Strong market position if approved, given Fosun&#8217;s established commercial infrastructure in China<\/li>\n\n\n\n<li><strong>Global Impact:<\/strong> Success in China could inform global development strategy and regulatory submissions<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding Fosun Pharma&#8217;s clinical development plans, partnership activities, and strategic objectives. Actual clinical trial results and regulatory outcomes may differ materially from current expectations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/download.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of download.\"><\/object><a id=\"wp-block-file--media-021f662a-1d6f-4f05-ba9c-42a8632103d4\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/download.pdf\">download<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/download.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-021f662a-1d6f-4f05-ba9c-42a8632103d4\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Fosun Pharma (SHA: 600196, HKG: 2196) has announced NMPA approval to initiate a Phase I&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[62,159,893,1072,18,892,1071],"class_list":["post-62031","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-clinical-trial-approval-initiation","tag-fosun-pharmaceutical","tag-hkg-2196","tag-nyse-teva","tag-pd-1-l1","tag-sha-600196","tag-teva-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE\u2122 Therapy FXB0871 in Solid Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Fosun Pharma (SHA: 600196, HKG: 2196) has announced NMPA approval to initiate a Phase I clinical trial of FXB0871, an anti-PD1-IL2 ATTENUKINE\u2122 therapy co-developed with Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), for the treatment of locally advanced or metastatic solid tumors. The approval expands the global clinical development of this innovative compound into China, complementing ongoing trials in the United States and Canada.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62031\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE\u2122 Therapy FXB0871 in Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"Fosun Pharma (SHA: 600196, HKG: 2196) has announced NMPA approval to initiate a Phase I clinical trial of FXB0871, an anti-PD1-IL2 ATTENUKINE\u2122 therapy co-developed with Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), for the treatment of locally advanced or metastatic solid tumors. The approval expands the global clinical development of this innovative compound into China, complementing ongoing trials in the United States and Canada.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62031\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-31T12:43:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-31T12:43:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62031#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62031\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE\u2122 Therapy FXB0871 in Solid Tumors\",\"datePublished\":\"2026-03-31T12:43:22+00:00\",\"dateModified\":\"2026-03-31T12:43:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62031\"},\"wordCount\":534,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Fosun Pharmaceutical\",\"HKG: 2196\",\"NYSE: TEVA\",\"PD-1\\\/L1\",\"SHA: 600196\",\"Teva Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62031#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62031\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62031\",\"name\":\"Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE\u2122 Therapy FXB0871 in Solid Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-31T12:43:22+00:00\",\"dateModified\":\"2026-03-31T12:43:23+00:00\",\"description\":\"Fosun Pharma (SHA: 600196, HKG: 2196) has announced NMPA approval to initiate a Phase I clinical trial of FXB0871, an anti-PD1-IL2 ATTENUKINE\u2122 therapy co-developed with Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), for the treatment of locally advanced or metastatic solid tumors. The approval expands the global clinical development of this innovative compound into China, complementing ongoing trials in the United States and Canada.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62031#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62031\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62031#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE\u2122 Therapy FXB0871 in Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE\u2122 Therapy FXB0871 in Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"Fosun Pharma (SHA: 600196, HKG: 2196) has announced NMPA approval to initiate a Phase I clinical trial of FXB0871, an anti-PD1-IL2 ATTENUKINE\u2122 therapy co-developed with Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), for the treatment of locally advanced or metastatic solid tumors. The approval expands the global clinical development of this innovative compound into China, complementing ongoing trials in the United States and Canada.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62031","og_locale":"en_US","og_type":"article","og_title":"Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE\u2122 Therapy FXB0871 in Solid Tumors","og_description":"Fosun Pharma (SHA: 600196, HKG: 2196) has announced NMPA approval to initiate a Phase I clinical trial of FXB0871, an anti-PD1-IL2 ATTENUKINE\u2122 therapy co-developed with Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), for the treatment of locally advanced or metastatic solid tumors. The approval expands the global clinical development of this innovative compound into China, complementing ongoing trials in the United States and Canada.","og_url":"https:\/\/flcube.com\/?p=62031","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-31T12:43:22+00:00","article_modified_time":"2026-03-31T12:43:23+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62031#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62031"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE\u2122 Therapy FXB0871 in Solid Tumors","datePublished":"2026-03-31T12:43:22+00:00","dateModified":"2026-03-31T12:43:23+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62031"},"wordCount":534,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Fosun Pharmaceutical","HKG: 2196","NYSE: TEVA","PD-1\/L1","SHA: 600196","Teva Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62031#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62031","url":"https:\/\/flcube.com\/?p=62031","name":"Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE\u2122 Therapy FXB0871 in Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-31T12:43:22+00:00","dateModified":"2026-03-31T12:43:23+00:00","description":"Fosun Pharma (SHA: 600196, HKG: 2196) has announced NMPA approval to initiate a Phase I clinical trial of FXB0871, an anti-PD1-IL2 ATTENUKINE\u2122 therapy co-developed with Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), for the treatment of locally advanced or metastatic solid tumors. The approval expands the global clinical development of this innovative compound into China, complementing ongoing trials in the United States and Canada.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62031#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62031"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62031#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE\u2122 Therapy FXB0871 in Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62031","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62031"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62031\/revisions"}],"predecessor-version":[{"id":62033,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62031\/revisions\/62033"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62031"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62031"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62031"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}